Claims Scope:

Allowed.  Issue fee due May 31, 2024. 

 

Sequence-specific Method of Manufacture and Composition Claims 

 

-ex vivo method of treating cells (claim 1)  

– method of treating leukocytes from HIV (+) patient (claim 13) 

– lentiviral vector (claim 25) 

– lentiviral system (claim 29) 

 

– sequence specific limitations include: 

1. 90% SEQ ID NO 31: CCR5, Vif and Tat (microRNA backbone plus guide, in order) 

1. 90% SEQ ID NO: 1, 2 and 3 CCR5, Vif And Tat (microRNA backbone plus guide, any order) 

1. SEQ ID NO: 97, 6 and 7 CCR5, Vif and Tat (guide, any order)  

 

*note – preimmunization agnostic  

*note – HIV status agnostic for broadest claim (claim 1)  

*note – no treatment-like claims